EdTreo

Your $800-a-month paradise has no stroke ambulance. 3 of 4 strokes hit people 65 or older. No night CT, no clot-buster, no thrombectomy team in the window. Price the ambulance, not just the rent. #WorldStrokeDay

No symptoms. No memory complaints. Just a routine blood draw. Two new studies asked whether that one sample could say something about your brain, years from now. Full piece at 7:51 AM ET.

The FDA Just Added a Vision Warning to Every GLP-1 Drug If you take Ozempic, Wegovy, Mounjaro, Zepbound, or any other GLP-1 medicine, a new warning is coming to your drug's label — and it concerns your eyes. On Monday, the FDA announced it will require the manufacturers of all GLP-1 medications to warn that these drugs can increase the risk of a rare condition called NAION. Not one brand. Not one drug. The whole class. What is NAION? NAION — non-arteritic anterior ischemic optic neuropathy — happens when blood flow to the optic nerve, the cable carrying vision from your eye to your brain, suddenly drops. The result is sudden, painless vision loss, usually in one eye. People often notice it on waking. And it can be permanent. How big is the risk, actually? This is where the headline sounds scarier than the numbers, so let's do the numbers. The FDA analyzed more than 125 clinical trials. Among people taking a GLP-1 medicine for at least a year, NAION occurred in about 6 out of every 100,000 patients. Among people on placebo or other glucose-lowering medicines, it was fewer than 4 out of 100,000. So the risk does look higher on the drug than off it — that is why the warning exists. But in absolute terms, we are talking about a few extra cases per hundred thousand people per year. Rare stays rare. The FDA also said cases have been reported for every GLP-1 product currently on the market, which is exactly why the warning is class-wide. The inquiry began after a 2024 paper first tied this condition to semaglutide. Regulators have been digging ever since, and Monday's announcement is where it landed. What should you do if you take one? Three things. First, don't stop your medication on your own. These drugs prevent heart attacks, strokes, and kidney damage — common, serious dangers that dwarf this rare one. Quitting suddenly trades a tiny risk for much bigger ones. Second, know the one symptom that matters: sudden vision loss in one eye. That is a same-day emergency — eye doctor or emergency department, no waiting to see if it improves. True whether or not you take a GLP-1, but it matters more now. Third, raise it at your next visit, especially if you already have eye disease. The right call is individual, and your doctor can weigh your personal risk. The honest caveat A warning like this is a signal, not a verdict. It comes from trial data and adverse-event reports — patterns that show an association, not proof the drug caused each case. The FDA's job is to flag the signal so patients and doctors can watch for it. That is what happened here. Bottom line: a rare risk, now on the label, worth knowing about — not a reason to panic, and not a reason to quietly stop a medicine that is helping you. --- I'm an Internal Medicine physician. I translate new medical research into plain English — what it actually means for you. Source: FDA announcement, Nov 9, 2026, as reported by the Washington Post and the Associated Press, via the Cleveland Clinic Internal Medicine Briefing.

# Exercise Matched Therapy for Depression in Trials In head-to-head trials, exercise eased depression about as much as talk therapy — and about as much as antidepressant medication. That is not a wellness slogan. It is the conclusion of the most careful evidence summary we have, updated this year, with its limits stated plainly. The Cochrane review pooled 73 randomized trials with at least 4,985 adults with depression. Against no treatment or a control, exercise reduced symptoms by a moderate-to-large amount: standardized mean difference −0.67, 95% confidence interval −0.82 to −0.52, across 57 trials — though that evidence was rated low certainty. Against psychological therapy, in 10 trials with 414 people, there was little to no difference: SMD 0.03, interval −0.16 to 0.23, rated moderate certainty. Against medication, in 5 trials with 330 people, again little to no difference: SMD −0.11, rated low certainty. A second, larger umbrella review in the British Journal of Sports Medicine stacked 81 meta-analyses, 1,079 component trials, and 79,551 participants. Exercise reduced depression symptoms overall, SMD −0.61, and anxiety symptoms, SMD −0.47. Aerobic exercise — walking, running, cycling, swimming — showed the largest effects, and group-based, supervised formats did best for depression. The strongest response in any group was in adults aged 18 to 30, SMD −0.81, with postnatal women close behind. Moderate intensity looked better than light or vigorous in the Cochrane analysis. What this means for you: exercise belongs in the depression treatment conversation as a real option with trial evidence behind it — especially aerobic, done with other people or with supervision, for at least a few months. For younger adults and new mothers, who often face the longest waits for therapy, the signal was strongest. What it does not mean: it does not mean quit your medication or cancel therapy and go for a jog. The head-to-head trials were few and small, participants cannot be blinded to exercise, and when analysts kept only the most rigorous trials the benefit shrank, though it stayed significant. Long-term follow-up was rare, so nobody knows how well the benefit holds after a program ends. Depression can be dangerous, and severe symptoms need direct care, not a fitness plan alone. The takeaway: think of exercise as a treatment that earned its seat at the table — comparable in these trials, cheap, and good for the heart and brain at the same time. The honest prescription is "in addition to, and sometimes alongside instead of waiting for" — decided with your clinician, never instead of urgent help. I first posted the short version here: Sources: Clegg et al., Cochrane Database of Systematic Reviews 2026, DOI 10.1002/14651858.CD004366.pub7 · Munro et al., British Journal of Sports Medicine 2026;60:590–599, DOI 10.1136/bjsports-2025-110301 — bjsm.bmj.com/content/early/2… I translate one new study into plain English at a time. Follow along if that is useful to you. nitter.gq/EdisonTanEdtreo/status…

73 trials. Nearly 5,000 adults. Exercise went head-to-head with talk therapy, and head-to-head with antidepressants, for depression. The result is not what most people expect. Full piece at 1:51 PM ET.

Stopping a Statin After 70: The STREAM Trial "Can I stop my statin?" — the STREAM trial finally tested it. Adults 70+ with multiple conditions and no heart disease: stopping was noninferior to continuing at 2 years (96.5 vs 98.5 event-free weeks). But events leaned the other way — 10.7% vs 8.2%. Not a free pass to quit. A conversation, with data. Source: STREAM, NEJM

Evolocumab vs Ezetimibe: 20% Fewer Heart Attacks Two cholesterol drugs, head-to-head in the real world — and it wasn't close. Evolocumab (Repatha) vs ezetimibe (Zetia): 20% lower rate of heart attacks, fatal and nonfatal, over four years. Not a placebo trial — actual practice. Source: American Journal of Preventive Cardiology

Made with the Muse app. muse.ai/join

Alzheimer's that starts early doesn't just start sooner — it loads the brain with more tau. Tau PET scans: 390 early-onset patients vs 211 late-onset — the early-onset group carried more extensive tau deposits. Same disease. A heavier burden, sooner. Source: Science Translational Medicine (LEADS + ADNI)

Made with the Muse app. muse.ai/join

Made with the Muse app. muse.ai/join

Back Pain That Lingers May Start With Mood, Not Just Muscle When back pain becomes chronic, we usually blame the spine. A review of 15 studies found two of the clearest predictors were not on an MRI: depression with distress, and fear of movement. That does not make the pain imaginary. It makes the treatment plan incomplete if it only treats tissue. The review, published in the European Journal of Pain in 2026, asked a narrow question: which physical, psychophysical, or psychological factors measured early predict persistent or recurrent non-specific low back pain, pain intensity, or disability later? The authors searched nine databases through January 2025, including MEDLINE, EMBASE, PsycINFO, PubMed, and CINAHL. Fifteen studies were included, all addressing persistent pain. Baseline enrollment across the review was about 15,522 people, with about 14,119 at follow-up, and follow-up ranged from 3 months to 6 years. The team examined one physical domain, trunk kinematics; one psychophysical domain, pain sensitivity; and seven psychological domains, including depression and distress, anxiety, fear avoidance, catastrophizing, somatization, coping, and self-efficacy. Only two psychological signals reached statistical significance in the meta-analysis. Depression and distress predicted persistent low back pain and disability across 7 studies and 15,778 participants: standardized beta 0.28, 95% confidence interval 0.04 to 0.53, p = 0.024. Fear avoidance, the belief that movement will cause harm and should be avoided, also predicted persistence across a smaller group of 1,105 participants: beta 0.24, 95% confidence interval 0.00 to 0.49, p = 0.049. Those are modest effects, not destiny. A beta of 0.28 does not mean mood explains most back pain. It means, on average, people with more depression and distress at baseline were measurably more likely to still have pain and disability later, even in studies designed to look for physical predictors too. The physical predictors did not produce the clean story patients expect. Evidence for trunk movement and pain sensitivity as predictors was limited. That does not prove mechanics are irrelevant. What this means for you: if back pain is lasting beyond the early weeks, mood, sleep, stress load, and fear of movement belong in the same conversation as exercise, medication, and imaging. Screening for depression in persistent back pain is not a detour from medical care. On this evidence, it is part of prognosis. Gradual, guided movement also matters precisely because fear avoidance predicts a worse course. What it does not mean: it does not mean pain is caused by attitude, or that treating depression alone will fix a back. The authors rated certainty of evidence as very low to low across predictor domains. Heterogeneity between studies was substantial, for depression and distress an I-squared of 85.8%, and many included studies carried high risk of bias. Prediction is also not causation: depression may worsen pain, pain may deepen depression, and both may track with poor sleep and less activity. The takeaway: persistent back pain is a whole-person prognosis problem. Ask about the back, and ask about mood and fear of movement too. The earlier both are addressed, the less either gets to entrench the other. I first posted the short version here: Sources: European Journal of Pain 2026, DOI 10.1002/ejp.70358 — pmc.ncbi.nlm.nih.gov/article… I translate one new study into plain English at a time. Follow along if that is useful to you. nitter.gq/EdisonTanEdtreo/status…

She Needed Epinephrine. First, Urgent Care Asked for $400 Her throat was tightening after a wasp sting. A clinician had already diagnosed anaphylaxis and said she needed epinephrine. Then she was told to pay $400 first. That sequence is the whole story, and it teaches a distinction every family should know before an emergency, not during one. Stephanie Rowell, 53, of Round Hill, Virginia, was stung on her parents' porch in July, per KFF Health News (Oct 29, 2026). Her arm felt on fire, she itched all over, and her face swelled and reddened. She took Benadryl. Her father drove toward the nearest emergency room, about 25 minutes away. Ten minutes into the drive they saw a TruHealthNow urgent care in Purcellville and stopped, hoping for faster help. Rowell had been uninsured since 2025. A nurse practitioner examined her, quickly diagnosed anaphylaxis, and advised a shot of epinephrine. Then, Rowell said, a medical assistant told her she had to pay $400 up front. She retrieved her wallet from her father and handed over her debit card. After payment, she received the shot. Within minutes her throat loosened. Staff monitored her for 30 minutes. Her total bill was $605: $400 for the medication, $40 to administer it, and $165 for the visit. KFF noted a generic auto-injector costs about $175 through GoodRx. Rowell said the price was not her complaint — paying before treatment was. She recalled asking if they would have let her die without the money, and being told that was policy. TruHealthNow tells it differently. Officials confirmed payment was asked before the shot, but said she had been judged stable, payment was requested while the injection was prepared, and it did not delay treatment. The CEO said policy is to give the shot and worry about money later. The legal line underneath: federal EMTALA law requires hospital emergency departments to screen and stabilize anyone, regardless of ability to pay. Urgent care centers generally do not fall under EMTALA unless hospital-owned, and they are built mainly for non-life-threatening problems. What this means for you: trouble breathing, throat tightening, chest pain, or fainting after a sting or food exposure is ER or 911 territory. If you carry an auto-injector, use it and still get emergency care. What it does not mean: it does not mean every urgent care would do this, or that this clinic admits delaying care. The accounts differ on delay and stability. The confirmed fact is narrower and still important: payment was requested before the shot in a diagnosed case of anaphylaxis. The takeaway: know which door is which before you need one. An ER cannot hold stabilizing care for payment. An urgent care usually can ask up front. In anaphylaxis, minutes matter, and epinephrine first is the standard everyone quoted in this story agreed on. I first posted the short version here: Sources: Galewitz, KFF Health News, Oct 29, 2026 — kffhealthnews.org/health-ind… I translate one new study, and the occasional health-system story, into plain English at a time. Follow along if that is useful to you. nitter.gq/EdisonTanEdtreo/status…